oncology
Merck and Selvita form oncology partnership
November 2, 2015Research and Development, Sales and Marketing Merck, Selvita, collaboration, oncology
Merck has entered a three-year agreement with Selvita to validate new therapeutic concepts in the field of oncology. The aim …
Counting the true cost of the Cancer Drugs Fund cuts
September 14, 2015Research and Development Cancer, Cancer Drugs Fund, NHS, clinical trials, cuts, oncology
Leading figures from the pharma industry and cancer charities reacted with dismay to the recent cuts to the Cancer Drugs …
How ‘deep reading’ of the scientific literature will benefit pharma
September 3, 2015Research and Development Big Data, Cancer, Data Mining, R&D, literature search, oncology
The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …
AstraZeneca and Peregrine in immuno-oncology collaboration
August 24, 2015Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours
AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …
Merck in immuno-oncology collaboration with major cancer research centre
August 14, 2015Research and Development Cancer, Merck, keytruda, oncology
Merck is teaming up with the University of Texas to evaluate Merck’s anti-PD-1 therapy, Keytruda, in combination with other treatmentsA team …
MedImmune and Inovio collaborate on cancer vaccine
August 11, 2015Manufacturing and Production, Research and Development AstraZeneca, HPV, Inovio, MedImmune, cancer vaccines, cervical cancer, oncology
MedImmune has entered into a license agreement and collaboration with Inovio, a biotechnology company developing DNA-based immunotherapies for cancer and …
Amgen bets on immunotherapy future
June 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, immunotherapy, oncology, oncolytic, tom lillie
When we speak to Tom Lillie he’s brimming with excitement about the future for Amgen in oncology and the future …
Lilly and AstraZeneca collaborate on cancer trials
May 29, 2015Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I
AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
Industry awaits key immunotherapy results at ASCO
May 20, 2015Research and Development, Sales and Marketing ASCO, Cancer, oncology, pharma
This year’s American Society of Clinical Oncology (ASCO) conference has a strong focus on immunotherapy, as pharma ramps up its …
Baxter buys cancer portfolio for $900 million
May 13, 2015Research and Development, Sales and Marketing Cancer, Oncaspar, Sigma-Tau Finanziaria, baxter, oncology
Baxter is buying leukaemia treatment Oncaspar from Italian firm Sigma-Tau Finanziaria for $900 million as the US firm looks to …
Worldwide cancer spending tops $100 billion
May 5, 2015Research and Development, Sales and Marketing Cancer, IMS Health, keytruda, oncology
Over $100 billion was spent on cancer medicines across the world last year as a new generation of drugs begins …
Two oncology successes for Pfizer
April 22, 2015Research and Development, Sales and Marketing Cancer, FDA, Inotuzumab ozogamicin, NSCLC, Pfizer, Xalkori, oncology
Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its …
Merck KGaA and Pfizer alliance begins lung cancer study
April 21, 2015Research and Development, Sales and Marketing Merck KGaA, Pfizer, avelumab, keytruda, oncology, opdivo
Merck KGaA and Pfizer have enrolled and treated the first patient in a late-stage study of their anti-PD1 cancer immunotherapy …
AstraZeneca bags another FDA orphan status in cancer
April 17, 2015Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib
The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
